Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

Clinical trial NCT04029038 · WITHDRAWN

Trial details

NCT number: NCT04029038
Sponsor: M.D. Anderson Cancer Center
Status: WITHDRAWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

CD19 Positive CD22 Positive Minimal Residual Disease Progressive Disease Recurrent B Acute Lymphoblastic Leukemia Recurrent Chronic Lymphocytic Leukemia Recurrent Non-Hodgkin Lymphoma Refractory B Acute Lymphoblastic Leukemia Refractory Chronic Lymphocytic Leukemia Refractory Non-Hodgkin Lymphoma

Start date: 2019-05-15
Primary completion: 2022-11-16
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.